Barclays PLC Purchases 245,909 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Barclays PLC boosted its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 106.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 476,974 shares of the medical device company's stock after buying an additional 245,909 shares during the quarter. Barclays PLC owned about 0.73% of Tandem Diabetes Care worth $17,180,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Baillie Gifford & Co. raised its holdings in Tandem Diabetes Care by 235.7% in the 4th quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company's stock worth $26,875,000 after acquiring an additional 523,843 shares during the period. GW&K Investment Management LLC lifted its holdings in shares of Tandem Diabetes Care by 18.0% during the fourth quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock worth $76,488,000 after buying an additional 323,674 shares during the last quarter. Stephens Investment Management Group LLC grew its stake in shares of Tandem Diabetes Care by 22.1% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company's stock worth $56,040,000 after acquiring an additional 281,327 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in Tandem Diabetes Care by 89.3% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 515,062 shares of the medical device company's stock worth $18,553,000 after acquiring an additional 242,965 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Tandem Diabetes Care by 397.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 301,614 shares of the medical device company's stock valued at $11,121,000 after purchasing an additional 240,966 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on TNDM. Royal Bank of Canada dropped their price objective on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a report on Thursday, February 27th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $63.00 price target on shares of Tandem Diabetes Care in a report on Wednesday, February 26th. Robert W. Baird decreased their price objective on Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating on the stock in a report on Thursday, February 27th. Wells Fargo & Company restated an "equal weight" rating and issued a $22.00 target price (down from $38.00) on shares of Tandem Diabetes Care in a research note on Monday, March 3rd. Finally, Sanford C. Bernstein downgraded shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $35.00 to $25.00 in a research note on Friday, February 28th. Eight research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $43.88.

Tandem Diabetes Care Trading Up 6.8 %

Shares of Tandem Diabetes Care stock traded up $1.13 on Thursday, hitting $17.70. 993,274 shares of the company's stock traded hands, compared to its average volume of 1,501,646. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. Tandem Diabetes Care, Inc. has a one year low of $15.75 and a one year high of $53.69. The firm's 50-day moving average price is $20.78 and its two-hundred day moving average price is $29.60. The stock has a market capitalization of $1.18 billion, a PE ratio of -9.17 and a beta of 1.52.

Insider Buying and Selling at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos purchased 10,538 shares of Tandem Diabetes Care stock in a transaction dated Friday, March 7th. The stock was bought at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the acquisition, the chief operating officer now directly owns 10,538 shares of the company's stock, valued at $190,948.56. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.20% of the company's stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.